Skip to content

Released May 9, 2016, after the close

10-Q filed May 9, 2016, 39 days after period end · 0001193125-16-583808

Q1 2016 · 10-Q
Revenue—
Net Income-$27.06MN/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.75N/M vs Q1 2015N/M vs Q4 2015
Operating Income-$27,349,000N/M
Operating Cash Flow-$23,165,000N/M
Free Cash Flowderived-$23,204,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2016Q1 2015Q1 2014Q1 2013
Revenue——$171.00K$233.00K
Net Income-$27.06M-$26.07M-$13.69M—
EPS Diluted-$0.75-$0.74-$0.46-$2.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR